Vacinação contra o papilomavírus humano e rastreamento de lesões anais
DOI:
https://doi.org/10.5327/2237-4574-238Resumo
***
Referências
Karita HCS, Magaret AS, Doody DR, Schouten JT, Mao C, Huh WK, et al. Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): a randomized, double-blind, placebo-controlled trial. Int J Cancer. 2026;158(11):2983-94. https://doi.org/10.1002/ijc.70366
Wilkin TJ, Chen H, Cespedes MS, Leon-Cruz JT, Godfrey C, Chiao EY, et al. A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018;67(9):1339-46. https://doi.org/10.1093/cid/ciy274
Bennis SL, Yared NF, Horvath KJ, Baker JV, Waterboer T, Thyagarajan B, et al. HPV vaccination status in HIV-negative MSM and its association with high-risk HPV detection using HPV serology and anorectal swabs. Vaccines (Basel). 2024;12(10):1154. https://doi.org/10.3390/vaccines12101154
Albuquerque A, Fontes F. Recent guidelines on anal cancer screening: a systematic review. J Low Genit Tract Dis. 2025;29(2):180-5. https://doi.org/10.1097/lgt.0000000000000878